A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer

Pulmonary Medicine

Volumn , Issue , 2012, Pages

  Patel, Pretesh R ^a   Yoo, David S ^a   Niibe, Yuzuru ^b   Urbanic, James J ^c   Salama, Joseph K ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMMUNOMODULATING AGENT; OXALIPLATIN; PACLITAXEL;

BRAIN METASTASIS; CANCER THERAPY; CHEMOEMBOLIZATION; GENE MUTATION; HUMAN; IMAGE GUIDED RADIOTHERAPY; LUNG NON SMALL CELL CANCER; METASTASIS; OLIGOMETASTASIS; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW; STEREOTACTIC RADIOSURGERY;

EID: 84876510572     PISSN: 20901836     EISSN: 20901844     Source Type: Journal    
DOI: 10.1155/2012/480961     Document Type: Review

References (69)

1. Jemal A., Global cancer statistics. CA-A Cancer Journal for Clinicians 2010 61 69 90
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M. J., Cancer statistics, 2007. CA-A Cancer Journal for Clinicians 2007 57 1 43 66 2-s2.0-33846457870 10.3322/canjclin.57.1.43 (Pubitemid 46148091)
3. Fossella F., Pereira J. R., Von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., Mattson K. V., Ramlau R., Szczsna A., Fidias P., Millward M., Belani C. P., Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group. Journal of Clinical Oncology 2003 21 16 3016 3024 2-s2.0-0042413836 10.1200/JCO.2003.12.046 (Pubitemid 46606280)
4. Douillard J. Y., Laporte S., Fossella F., Georgoulias V., Pujol J. L., Kubota K., Monnier A., Kudoh S., Rubio J. E., Cucherat M., Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. Journal of Thoracic Oncology 2007 2 10 939 946 2-s2.0-34848818029 10.1097/JTO.0b013e318153fa2b (Pubitemid 47511598)
5. Lara P. N. Jr., Douillard J.-Y., Nakagawa K., Von Pawel J., McKeage M. J., Albert I., Losonczy G., Reck M., Heo D.-S., Fan X., Fandi A., Scagliotti G. Jr., Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. Journal of Clinical Oncology 2011 29 22 2965 2971 2-s2.0-80051638135 10.1200/JCO.2011.35.0660
6. Weissman C. H., A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology 2011 6 358 364 10.1097/JTO.0b013e3181ffe8ef
7. Fossella F. V., DeVore R., Kerr R. N., Crawford J., Natale R. R., Dunphy F., Kalman L., Miller V., Lee J. S., Moore M., Gandara D., Karp D., Vokes E., Kris M., Kim Y., Gamza F., Hammershaimb L., Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. Journal of Clinical Oncology 2000 18 12 2354 2362 2-s2.0-0034095853 (Pubitemid 30415821)
8. Shepherd F. A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., Levitan N., Gressot L., Vincent M., Burkes R., Coughlin S., Kim Y., Berille J., Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy. Journal of Clinical Oncology 2000 18 10 2095 2103 2-s2.0-0034069620 (Pubitemid 30324363)
9. Shepherd F. A., Pereira J. R., Ciuleanu T., Eng H. T., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., Van Kooten M., Dediu M., Findlay B., Tu D., Johnston D., Bezjak A., Clark G., Santabárbara P., Seymour L., Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine 2005 353 2 123 132 2-s2.0-22044445517 10.1056/NEJMoa050753 (Pubitemid 41058344)
10. Hellman S., Weichselbaum R. R., Oligometastases. Journal of Clinical Oncology 1995 13 1 8 10 2-s2.0-0028836101
11. Hellman S., Weichselbaum R. R., Importance of local control in an era of systematic therapy. Nature Clinical Practice Oncology 2005 2 2 60 61 2-s2.0-20344362646 10.1038/ncponc0075 (Pubitemid 40790133)
12. Niibe Y., Hayakawa K., Oligometastases and oligo-recurrence: the new era of cancer therapy. Japanese Journal of Clinical Oncology 2010 40 2 107 111 Article numberhyp167 2-s2.0-77449085961 10.1093/jjco/hyp167
13. Niibe Y., Oligometastases of Brain Only in Patients with Non-small Cell Lung Cancer (NSCLC) Treated with Stereotactic Irradiation (STI): a Multi-institutional Study in Japan. International Journal of Radiation Oncology, Biology 2010 78, article S497
14. Chee K. G., Nguyen D. V., Brown M., Gandara D. R., Wun T., Lara P. N., Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Archives of Internal Medicine 2008 168 14 1541 1549 2-s2.0-49449085251 10.1001/archinte.168.14.1541
15. Mehta N., Mauer A. M., Hellman S., Haraf D. J., Cohen E. E., Vokes E. E., Weichselbaum R. R., Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. International Journal of Oncology 2004 25 6 1677 1683 2-s2.0-16644368518
16. Rusthoven K. E., Hammerman S. F., Kavanagh B. D., Birtwhistle M. J., Stares M., Camidge D. R., Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncologica 2009 48 4 578 583 2-s2.0-65549125983 10.1080/02841860802662722
17. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., Simms L., Shepherd F. A., The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009 14 3 253 263 2-s2.0-64049115311 10.1634/theoncologist.2008-0232
18. Scagliotti G. V., Parikh P., Von Pawel J., Biesma B., Vansteenkiste J., Manegold C., Serwatowski P., Gatzemeier U., Digumarti R., Zukin M., Lee J. S., Mellemgaard A., Park K., Patil S., Rolski J., Goksel T., De Marinis F., Simms L., Sugarman K. P., Gandara D., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology 2008 26 21 3543 3551 2-s2.0-49049089802 10.1200/JCO.2007.15.0375
19. Sandler A., Gray R., Perry M. C., Brahmer J., Schiller J. H., Dowlati A., Lilenbaum R., Johnson D. H., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. The New England Journal of Medicine 2006 355 24 2542 2550 2-s2.0-33846423226 10.1056/NEJMoa061884 (Pubitemid 44917502)
20. Zhou C., Wu Y. L., Chen G., Feng J., Liu X. Q., Wang C., Zhang S., Wang J., Zhou S., Ren S., Lu S., Zhang L., Hu C., Hu C., Luo Y., Chen L., Ye M., Huang J., Zhi X., Zhang Y., Xiu Q., Ma J., Zhang L., You C., Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology 2011 12 8 735 742 2-s2.0-79960889662 10.1016/S1470-2045(11)70184-X
21. Shaw A. T., Yeap B. Y., Solomon B. J., Riely G. J., Gainor J., Engelman J. A., Shapiro G. I., Costa D. B., Ou S. H. I., Butaney M., Salgia R., Maki R. G., Varella-Garcia M., Doebele R. C., Bang Y.-J., Kulig K., Selaru P., Tang Y., Wilner K. D., Kwak E. L., Clark J. W., Iafrate A. J., Camidge D. R., Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. The Lancet Oncology 2011 12 11 1004 1012 2-s2.0-80053386829 10.1016/S1470-2045(11)70232-7
22. Ramaswamy G., Comprehensive genomic characterization of squamous cell carcinoma of the lung. Journal of Clinical Oncology 2012 30. supplement, abstract no. 7006
23. Flannery T. W., Suntharalingam M., Kwok Y., Koffman B. H., Amin P. P., Chin L. S., Nicol B., Fowler Z., Young A. B., Regine W. F., Gamma knife stereotactic radiosurgery for synchronous versus metachronous solitary brain metastases from non-small cell lung cancer. Lung Cancer 2003 42 3 327 333 2-s2.0-10744222978 10.1016/S0169-5002(03)00357-X (Pubitemid 37468546)
24. Flannery T. W., Suntharalingam M., Regine W. F., Chin L. S., Krasna M. J., Shehata M. K., Edelman M. J., Kremer M., Patchell R. A., Kwok Y., Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. International Journal of Radiation Oncology Biology Physics 2008 72 1 19 23 2-s2.0-79960045178 10.1016/j.ijrobp.2007.12.031
25. Girard N., Cottin V., Tronc F., Etienne-Mastroianni B., Thivolet-Bejui F., Honnorat J., Guyotat J., Souquet P.-J., Cordier J.-F., Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases. Lung Cancer 2006 53 1 51 58 2-s2.0-33744937050 10.1016/j.lungcan.2006.01.014 (Pubitemid 43841936)
26. Cheruvu P., Metcalfe S. K., Metcalfe J., Chen Y., Okunieff P., Milano M. T., Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer. Radiation Oncology 2011 6 1, article 80 2-s2.0-79959685126 10.1186/1748-717X-6-80
27. Khan A. J., Mehta P. S., Zusag T. W., Bonomi P. D., Penfield Faber L., Shott S., Abrams R. A., Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiotherapy and Oncology 2006 81 2 163 167 2-s2.0-33751211247 10.1016/j.radonc.2006.09.006 (Pubitemid 44780782)
28. Hasselle M. D., Haraf D. J., Rusthoven K. E., Golden D. W., Salgia R., Villaflor V. M., Shah N., Hoffman P. C., Chmura S. J., Connell P. P., Vokes E. E., Weichselbaum R. R., Salama J. K., Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. Journal of Thoracic Oncology 2012 7 2 376 381 2-s2.0-84858332431 10.1097/JTO.0b013e31824166a5
29. De Ruysscher D., Wanders R., Wanders R., van Baardwijk A., Dingemans A. M., Reymen B., Houben R., Bootsma G., Pitz C., van Eijsden L., Geraedts W., Baumert B. G., Lambin P., Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (NCT01282450). Journal of Thoracic Oncology 2012 7 10 1547 1555
30. Schild S.,. Radiation Therapy or Observation after Chemotherapy in Treating Patients with Stage IV Non-Small Cell Lung Cancer. ClinicalTrials.gov NCT00776100, 2008, http://clinicaltrials.gov/ct2/show/NCT00776100
31. Vokes E.,. The Synergistic Metastases Annihilation with Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC). ClinicalTrials.gov NCT00887315, 2009, http://clinicaltrials.gov/show/NCT00887315
32. Urbanic J.,. Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer. ClinicalTrials.gov NCT01185639, 2010, http://clinicaltrials.gov/show/NCT01185639
33. Wronski M., Arbit E., Burt M., Galicich J. H., Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991. Journal of Neurosurgery 1995 83 4 605 616 2-s2.0-0029131199
34. Pastorino U., Buyse M., Friedel G., Ginsberg R. J., Girard P., Goldstraw P., Johnston M., McCormack P., Pass H., Putnam J.B. Jr., Rusch V. W., Nazari S., Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. Journal of Thoracic and Cardiovascular Surgery 1997 113 1 37 49 2-s2.0-13044270974 10.1016/S0022-5223(97)70397-0 (Pubitemid 27034340)
35. Fong Y., Cohen A. M., Fortner J. G., Enker W. E., Turnbull A. D., Coit D. G., Marrero A. M., Prasad M., Blumgart L. H., Brennan M. F., Liver resection for colorectal metastases. Journal of Clinical Oncology 1997 15 3 938 946 2-s2.0-0031052731 (Pubitemid 27106275)
36. Tanvetyanon T., Robinson L. A., Schell M. J., Strong V. E., Kapoor R., Coit D. G., Bepler G., Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. Journal of Clinical Oncology 2008 26 7 1142 1147 2-s2.0-41949119176 10.1200/JCO.2007.14.2091
37. Andrews D. W., Scott C. B., Sperduto P. W., Flanders A. E., Gaspar L. E., Schell M. C., Werner-Wasik M., Demas W., Ryu J., Bahary J.-P., Souhami L., Rotman M., Mehta M. P., Curran Jr. W. J., Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. The Lancet 2004 363 9422 1665 1672 2-s2.0-20144387265 10.1016/S0140-6736(04)16250-8 (Pubitemid 38670323)
38. Shehata M. K., Young B., Reid B., Patchell R. A., Clair W. S., Sims J., Sanders M., Meigooni A., Mohiuddin M., Regine W. F., Stereotatic radiosurgery of 468 brain metastases ≤2 cm: implications for SRS dose and whole brain radiation therapy. International Journal of Radiation Oncology Biology Physics 2004 59 1 87 93 2-s2.0-7244236424 10.1016/j.ijrobp.2003.10.009 (Pubitemid 38501511)
39. Timmerman R., Paulus R., Galvin J., Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010 303 1070 1076
40. Onishi H., Shirato H., Nagata Y., Hiraoka M., Fujino M., Gomi K., Niibe Y., Karasawa K., Hayakawa K., Takai Y., Kimura T., Takeda A., Ouchi A., Hareyama M., Kokubo M., Hara R., Itami J., Yamada K., Araki T., Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. Journal of Thoracic Oncology 2007 2 7 S94 S100 2-s2.0-34547510573 10.1097/JTO. 0b013e318074de34 (Pubitemid 47183602)
41. Ettinger D. S., Non-small cell lung cancer. JNCCN 2010 8 740 801
42. Boike T. P., Lotan Y., Cho L. C., Brindle J., DeRose P., Xie X.-J., Yan J., Foster R., Pistenmaa D., Perkins A., Cooley S., Timmerman R., Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. 2011 29 15 2020 2026 2-s2.0-79956328867 10.1200/JCO.2010.31.4377
43. King C. R., Brooks J. D., Gill H., Presti Jr. J. C., Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. International Journal of Radiation Oncology Biology Physics 2012 82 2 877 882 2-s2.0-84855825726 10.1016/j.ijrobp.2010.11.054
44. Chang D. T., Schellenberg D., Shen J., Kim J., Goodman K. A., Fisher G. A., Ford J. M., Desser T., Quon A., Koong A. C., Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009 115 3 665 672 2-s2.0-60049088476 10.1002/cncr.24059
45. Okunieff P., Petersen A. L., Philip A., Milano M. T., Katz A. W., Boros L., Schell M. C., Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncologica 2006 45 7 808 817 2-s2.0-33748325628 10.1080/02841860600908954 (Pubitemid 44423126)
46. Schefter T. E., Rusthoven K. E., Kavanagh B. D., Burri S. H., Chen C., Cardenes H., Chidel M. A., Pugh T. J., Kane M., Gaspar L. E., Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. Journal of Clinical Oncology 2009 27 10 1579 1584 2-s2.0-83555173457 10.1200/JCO.2008.19.6386
47. Schefter T. E., Rusthoven K. E., Kavanagh B. D., Cardenes H., Stieber V. W., Burri S. H., Feigenberg S. J., Chidel M. A., Pugh T. J., Franklin W., Kane M., Gaspar L. E., Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. Journal of Clinical Oncology 2009 27 10 1572 1578 2-s2.0-70350576874 10.1200/JCO.2008.19.6329
48. Katz A. W., Carey-Sampson M., Muhs A. G., Milano M. T., Schell M. C., Okunieff P., Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. International Journal of Radiation Oncology Biology Physics 2007 67 3 793 798 2-s2.0-34547850184 10.1016/j.ijrobp.2006.10.025 (Pubitemid 46215888)
49. Chang E. L., Shiu A. S., Mendel E., Mathews L. A., Mahajan A., Allen P. K., Weinberg J. S., Brown B. W., Wang X. S., Woo S. Y., Cleeland C., Maor M. H., Rhines L. D., Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. Journal of Neurosurgery 2007 7 2 151 160 2-s2.0-34547699263 10.3171/SPI-07/08/151 (Pubitemid 47219748)
50. Gerszten P. C., Burton S. A., Ozhasoglu C., Welch W. C., Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine 2007 32 2 193 199 2-s2.0-33846246264 10.1097/01.brs.0000251863.76595.a2 (Pubitemid 46105806)
51. Nelson J. W., Yoo D. S., Sampson J. H., Isaacs R. E., Larrier N. A., Marks L. B., Yin F.-F., Wu Q. J., Wang Z., Kirkpatrick J. P., Stereotactic body radiotherapy for lesions of the spine and paraspinal regions. International Journal of Radiation Oncology Biology Physics 2009 73 5 1369 1375 2-s2.0-62649160951 10.1016/j.ijrobp.2008.06.1949
52. Ryu S., Jin R., Jin J.-Y., Chen Q., Rock J., Anderson J., Movsas B., Pain control by image-guided radiosurgery for solitary spinal metastasis. Journal of Pain and Symptom Management 2008 35 3 292 298 2-s2.0-39549094685 10.1016/j.jpainsymman.2007.04.020
53. Garg A. K., Shiu A. S., Yang J., Wang X.-S., Allen P., Brown B. W., Grossman P., Frija E. K., Mcaleer M. F., Azeem S., Brown P. D., Rhines L. D., Chang E. L., Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases. Cancer 2012 118 20 5069 5077 2-s2.0-84859762509 10.1002/cncr.27530
54. Stinauer M. A., Kavanagh B. D., Schefter T. E., Gonzalez R., Flaig T., Lewis K., Robinson W., Chidel M., Glode M., Raben D., Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiation Oncology 2011 6 1, article 34 2-s2.0-79953740080 10.1186/1748-717X-6-34
55. Ranck M. C., Golden D. W., Corbin K. S., Hasselle M. D., Liauw S. L., Stadler W. M., Hahn O. M., Weichselbaum R. R., Salama J. K., Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. American Journal of Clinical Oncology. In press 2-s2.0-84861577031 10.1097/COC. 0b013e31825d52b2
56. Garcia-Barros M., Paris F., Cordon-Cardo C., Lyden D., Rafii S., Haimovitz-Friedman A., Fuks Z., Kolesnick R., Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003 300 5622 1155 1159 2-s2.0-0038626211 10.1126/science.1082504 (Pubitemid 36583102)
57. Fuks Z., Kolesnick R., Engaging the vascular component of the tumor response. Cancer Cell 2005 8 2 89 91 2-s2.0-23644445797 10.1016/j.ccr.2005.07. 014 (Pubitemid 41132735)
58. + T cells: changing strategies for cancer treatment. Blood 2009 114 3 589 595 2-s2.0-70149113060 10.1182/blood-2009-02-206870
59. Burnette B. C., Liang H., Lee Y., Chlewicki L., Khodarev N. N., Weichselbaum R. R., Fu Y.-X., Auh S. L., The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Research 2011 71 7 2488 2496 2-s2.0-79953295544 10.1158/0008-5472.CAN-10- 2820
60. Stamell E. F., Wolchok J. D., Gnjatic S., Lee N. Y., Brownell I., The abscopal effect associated with a systemic anti-melanoma immune response. International Journal of Radiation Oncology, Biology, Physics. In press 2-s2.0-84860593989 10.1016/j.ijrobp.2012.03.017
61. Postow M. A., Callahan M. K., Barker C. A., Immunologic correlates of the abscopal effect in a patient with melanoma. The New England Journal of Medicine 2012 366 10 925 931 2-s2.0-84857815877 10.1056/NEJMoa1112824
62. Ryan G. F., Ball D. L., Smith J. G., Treatment of brain metastases from primary lung cancer. 1995 31 2 273 278 2-s2.0-0028817624 10.1016/0360-3016(93) E0073-F
63. Lagerwaard F. J., Levendag P. C., Nowak P. J. C. M., Eijkenboom W. M. H., Hanssens P. E. J., Schmitz P. I. M., Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. International Journal of Radiation Oncology Biology Physics 1999 43 4 795 803 2-s2.0-0033054670 10.1016/S0360-3016(98)00442-8 (Pubitemid 29152652)
64. Villarreal-Garza C., de la Mata D., Zavala D. G., Macedo-Perez E. O., Arrieta O., Aggressive treatment of primary tumor in patients with non-small-cell lung cancer and exclusively brain metastases. Clinical Lung Cancer. In press 10.1016/j.cllc.2012.05.002
65. Iwasaki A., Shirakusa T., Yoshinaga Y., Enatsu S., Yamamoto M., Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor. European Journal of Cardio-Thoracic Surgery 2004 26 3 488 493 2-s2.0-4143122174 10.1016/j.ejcts. 2004.05.049 (Pubitemid 39091984)
66. Moazami N., Rice T. W., Rybicki L. A., Adelstein D. J., Murthy S. C., DeCamp M. M., Barnett G. H., Chidel M. A., Suh J. H., Blackstone E. H., Stage III non-small cell lung cancer and metachronous brain metastases. Journal of Thoracic and Cardiovascular Surgery 2002 124 1 113 122 2-s2.0-0036657517 10.1067/mtc.2002.121678
67. Abrahams J. M., Torchia M., Putt M., Kaiser L. R., Judy K. D., Risk factors affecting survival after brain metastases from non-small cell lung carcinoma: a follow-up study of 70 patients. Journal of Neurosurgery 2001 95 4 595 600 2-s2.0-0034765322 (Pubitemid 33031420)
68. Ishikawa H., Metcalfe S. K., Milano M. T., Zhang M., The impact of GM-CSF up-regulation by SBRT on overall survival of metastatic breast cancer patients. International Journal of Radiation Oncology Biology Physics 2009 75 3 S539
69. Lussier Y. A., Rosie Xing H., Salama J. K., MicroRNA expression characterizes oligometastasis(es). PLoS One 6 e28650 10.1371/journal.pone. 0028650